
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Therapy: Preclinical |
Authors' Affiliations: 1 Dartmouth Medical School and 2 Dartmouth College, Hanover, New Hampshire; 3 National Cancer Institute, Bethesda, Maryland; and 4 Case Western Reserve University School of Medicine, Cleveland, Ohio
Requests for reprints: John J. Letterio, Division of Pediatric Hematology Oncology, Rainbow Babies and Children's Hospital, 11100 Euclid Avenue, Cleveland OH 44106. Fax: 216-844-5431; E-mail: John.Letterio{at}uhhs.com.
Purpose: Excessive activity of the transcription factors known as signal transducers and activators of transcription (STAT) contributes to the development and progression of malignancy in many organs. It is, therefore, important to develop new drugs to control the STATs, particularly their phosphorylation state, which is required for their transcriptional activity.
Experimental Design: Myeloma and lung cancer cells were treated with the new synthetic triterpenoid CDDO-Imidazolide, and STAT phosphorylation and apoptosis were evaluated by immunoblotting and fluorescence-activated cell sorting analysis.
Results: We now report that CDDO-Imidazolide, previously shown to be a potent agent for control of inflammation, cell proliferation, and apoptosis, rapidly (within 30-60 minutes) and potently (at nanomolar levels) suppresses either constitutive or interleukin-6-induced STAT3 and STAT5 phosphorylation in human myeloma and lung cancer cells. Furthermore, in these cells, CDDO-Imidazolide also up-regulates critical inhibitors of STATs, such as suppressor of cytokine signaling-1 and SH2-containing phosphatase-1 (a tyrosine phosphatase). Moreover, gene array studies reported here show that CDDO-Imidazolide potently regulates the transcription of important genes that are targets of the STATs.
Conclusions: Our new data thus show that CDDO-Imidazolide is a potent suppressor of STAT signaling and provide a further mechanistic basis for future clinical use of this agent to control inflammation or cell proliferation.
This article has been cited by other articles:
![]() |
K. Liby, R. Risingsong, D. B. Royce, C. R. Williams, M. M. Yore, T. Honda, G. W. Gribble, W. W. Lamph, N. Vannini, I. Sogno, et al. Prevention and Treatment of Experimental Estrogen Receptor-Negative Mammary Carcinogenesis by the Synthetic Triterpenoid CDDO-Methyl Ester and the Rexinoid LG100268 Clin. Cancer Res., July 15, 2008; 14(14): 4556 - 4563. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Ahmad, D. Raina, C. Meyer, and D. Kufe Triterpenoid CDDO-Methyl Ester Inhibits the Janus-Activated Kinase-1 (JAK1)->Signal Transducer and Activator of Transcription-3 (STAT3) Pathway by Direct Inhibition of JAK1 and STAT3 Cancer Res., April 15, 2008; 68(8): 2920 - 2926. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Vannini, G. Lorusso, R. Cammarota, M. Barberis, D. M. Noonan, M. B. Sporn, and A. Albini The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent Mol. Cancer Ther., December 1, 2007; 6(12): 3139 - 3146. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Liby, D. B. Royce, R. Risingsong, C. R. Williams, M. D. Wood, R. A. Chandraratna, and M. B. Sporn A New Rexinoid, NRX194204, Prevents Carcinogenesis in Both the Lung and Mammary Gland Clin. Cancer Res., October 15, 2007; 13(20): 6237 - 6243. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Pathak, M. Bhutani, A. S. Nair, K. S. Ahn, A. Chakraborty, H. Kadara, S. Guha, G. Sethi, and B. B. Aggarwal Ursolic Acid Inhibits STAT3 Activation Pathway Leading to Suppression of Proliferation and Chemosensitization of Human Multiple Myeloma Cells Mol. Cancer Res., September 1, 2007; 5(9): 943 - 955. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Albini, D. M. Noonan, and N. Ferrari Molecular Pathways for Cancer Angioprevention Clin. Cancer Res., August 1, 2007; 13(15): 4320 - 4325. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Liby, T. Honda, C. R. Williams, R. Risingsong, D. B. Royce, N. Suh, A. T. Dinkova-Kostova, K. K. Stephenson, P. Talalay, C. Sundararajan, et al. Novel semisynthetic analogues of betulinic acid with diverse cytoprotective, antiproliferative, and proapoptotic activities Mol. Cancer Ther., July 1, 2007; 6(7): 2113 - 2119. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Liby, D. B. Royce, C. R. Williams, R. Risingsong, M. M. Yore, T. Honda, G. W. Gribble, E. Dmitrovsky, T. A. Sporn, and M. B. Sporn The Synthetic Triterpenoids CDDO-Methyl Ester and CDDO-Ethyl Amide Prevent Lung Cancer Induced by Vinyl Carbamate in A/J Mice Cancer Res., March 15, 2007; 67(6): 2414 - 2419. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Contreras-Shannon, O. Ochoa, S. M. Reyes-Reyna, D. Sun, J. E. Michalek, W. A. Kuziel, L. M. McManus, and P. K. Shireman Fat accumulation with altered inflammation and regeneration in skeletal muscle of CCR2-/- mice following ischemic injury Am J Physiol Cell Physiol, February 1, 2007; 292(2): C953 - C967. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Yore, K. T. Liby, T. Honda, G. W. Gribble, and M. B. Sporn The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-{kappa}B activation through direct inhibition of I{kappa}B kinase {beta} Mol. Cancer Ther., December 1, 2006; 5(12): 3232 - 3239. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |